Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with HIV: data from the PANNA Network.
Vera E BukkemsCoca NecsoiCarmen Hidalgo TenorioCoral GarciaIrene Alba AlejandreFabian WeissJohn S LambertAstrid van HulzenOlivier RichelLindsey H M Te BrakeEric van der MeulenDavid BurgerDeborah KonopnickiAngela Colbersnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
TAF plasma concentrations were reduced by about half in women living with HIV during third trimester of pregnancy, but remained above the predefined efficacy target in the majority of the pregnant women. TFV concentrations were reduced by approximately 30% during third trimester. Despite the observed exposure decrease, high virologic efficacy was observed in this study.